Patent search ap:("ST. JUDE CHILDREN'S RESEARCH HOSPITAL Page INC.") AND inv:"Benjamin YOUNGBLOOD"

1.

发明申请
DNMT3A KNOCK-OUT STAT5 ACTIVATED GENETICALLY ENGINEERED T-CELLS 有权

公开(公告)号：US20220226379A1

公开(公告)日：2022-07-21

申请号：US17602524

申请日：2020-04-08

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Stephen GOTTSCHALK , Giedre KRENCIUTE , Christopher PETERSEN , Benjamin YOUNGBLOOD

IPC: A61K35/17 , A61P35/02 , A61K35/545 , C12N9/10

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

2.

发明申请
T CELL GENE EXPRESSION ANALYSIS FOR USE IN T CELL THERAPIES 有权

公开(公告)号：US20220326216A1

公开(公告)日：2022-10-13

申请号：US17608079

申请日：2020-04-08

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Benjamin YOUNGBLOOD , Jeremy CRAWFORD , Yiping FAN , Caitlin ZEBLEY , Stephen GOTTSCHALK , Giedre KRENCIUTE , Christopher PETERSEN

IPC: G01N33/50 , C07K14/705 , A61K35/17

Abstract: The application provides T cell gene expression signatures that can be used to predict T cell therapy outcomes.

3.

发明申请
METHOD FOR PRESERVING DEVELOPMENTAL POTENTIAL OF IMMUNE CELLS USED FOR ADOPTIVE CELLULAR THERAPIES 有权

公开(公告)号：US20240366759A1

公开(公告)日：2024-11-07

申请号：US18572990

申请日：2022-06-21

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Benjamin YOUNGBLOOD , Giedre KRENCIUTE , Stephen GOTTSCHALK , Brooke PRINZING , Caitlin ZEBLEY

IPC: A61K39/00 , C12N5/0783 , C12N9/22 , C12N15/11 , C12N15/90

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and IL10 signaling pathway is enhanced. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

Patent Agency Ranking